- Home
- CDIO vs CMMB Comparison
CDIO vs CMMB Comparison
Compare CDIO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- CMMB
- Stock Information
- Founded
- CDIO 2017
- CMMB 2004
- Country
- CDIO United States
- CMMB Israel
- Employees
- CDIO N/A
- CMMB N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- CMMB Health Care
- Exchange
- CDIO Nasdaq
- CMMB Nasdaq
- Market Cap
- CDIO 19.5M
- CMMB 23.0M
- IPO Year
- CDIO N/A
- CMMB N/A
- Fundamental
- Price
- CDIO $4.53
- CMMB $1.21
- Analyst Decision
- CDIO Buy
- CMMB Strong Buy
- Analyst Count
- CDIO 1
- CMMB 2
- Target Price
- CDIO $2.00
- CMMB $9.00
- AVG Volume (30 Days)
- CDIO 68.6K
- CMMB 89.3K
- Earning Date
- CDIO 05-23-2025
- CMMB 05-27-2025
- Dividend Yield
- CDIO N/A
- CMMB N/A
- EPS Growth
- CDIO N/A
- CMMB N/A
- EPS
- CDIO N/A
- CMMB N/A
- Revenue
- CDIO $34,890.00
- CMMB N/A
- Revenue This Year
- CDIO $1,434.82
- CMMB N/A
- Revenue Next Year
- CDIO $4,661.91
- CMMB N/A
- P/E Ratio
- CDIO N/A
- CMMB N/A
- Revenue Growth
- CDIO 104.45
- CMMB N/A
- 52 Week Low
- CDIO $0.19
- CMMB $0.60
- 52 Week High
- CDIO $1.77
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- CDIO 29.92
- CMMB 46.51
- Support Level
- CDIO $4.50
- CMMB $1.15
- Resistance Level
- CDIO $14.46
- CMMB $1.31
- Average True Range (ATR)
- CDIO 1.69
- CMMB 0.09
- MACD
- CDIO -0.97
- CMMB -0.00
- Stochastic Oscillator
- CDIO 4.66
- CMMB 22.58
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.